BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Boga S, Alkim H, Koksal AR, Ozagari AA, Bayram M, Tekin Neijmann S, Sen I, Alkim C. Serum ST2 in inflammatory bowel disease: a potential biomarker for disease activity. J Investig Med 2016;64:1016-24. [PMID: 27001944 DOI: 10.1136/jim-2016-000062] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Hodzic Z, Schill EM, Bolock AM, Good M. IL-33 and the intestine: The good, the bad, and the inflammatory. Cytokine. 2017;100:1-10. [PMID: 28687373 DOI: 10.1016/j.cyto.2017.06.017] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 8.6] [Reference Citation Analysis]
2 Homsak E, Gruson D. Soluble ST2: A complex and diverse role in several diseases. Clin Chim Acta 2020;507:75-87. [PMID: 32305537 DOI: 10.1016/j.cca.2020.04.011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
3 Routy B, Letendre C, Enot D, Chénard-Poirier M, Mehraj V, Séguin NC, Guenda K, Gagnon K, Woerther PL, Ghez D, Lachance S. The influence of gut-decontamination prophylactic antibiotics on acute graft-versus-host disease and survival following allogeneic hematopoietic stem cell transplantation. Oncoimmunology 2017;6:e1258506. [PMID: 28197380 DOI: 10.1080/2162402X.2016.1258506] [Cited by in Crossref: 39] [Cited by in F6Publishing: 21] [Article Influence: 6.5] [Reference Citation Analysis]
4 Yuan C. IL-33 in autoimmunity; possible therapeutic target. International Immunopharmacology 2022;108:108887. [DOI: 10.1016/j.intimp.2022.108887] [Reference Citation Analysis]
5 Magro F, Lopes S, Silva M, Coelho R, Portela F, Branquinho D, Correia L, Fernandes S, Cravo M, Caldeira P, Tavares de Sousa H, Patita M, Lago P, Ramos J, Afonso J, Redondo I, Machado P, Philip G, Lopes J, Carneiro F. Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab. Therap Adv Gastroenterol 2019;12:1756284819869141. [PMID: 31516554 DOI: 10.1177/1756284819869141] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Yuan X, Chinnaswamy K, Stuckey JA, Yang CY. Computational Cosolvent Mapping Analysis Leads to Identify Salicylic Acid Analogs as Weak Inhibitors of ST2 and IL33 Binding. J Phys Chem B 2022. [PMID: 35294837 DOI: 10.1021/acs.jpcb.2c00341] [Reference Citation Analysis]
7 Liu X, Xiao Y, Pan Y, Li H, Zheng SG, Su W. The role of the IL-33/ST2 axis in autoimmune disorders: Friend or foe? Cytokine & Growth Factor Reviews 2019;50:60-74. [DOI: 10.1016/j.cytogfr.2019.04.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
8 Figliuolo da Paz VR, Jamwal DR, Kiela PR. Intestinal Regulatory T Cells. Adv Exp Med Biol 2021;1278:141-90. [PMID: 33523448 DOI: 10.1007/978-981-15-6407-9_9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Kourkoulis P, Kapizioni C, Michalopoulos G, Andreou N, Papaconstantinou I, Karamanolis G, Gazouli M. Novel potential biomarkers for the diagnosis and monitoring of patients with ulcerative colitis. European Journal of Gastroenterology & Hepatology 2019;31:1173-83. [DOI: 10.1097/meg.0000000000001490] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Ballesteros S, Domenech J, Velázquez A, Marcos R, Hernández A. Ex vivo exposure to different types of graphene-based nanomaterials consistently alters human blood secretome. J Hazard Mater 2021;414:125471. [PMID: 33647622 DOI: 10.1016/j.jhazmat.2021.125471] [Reference Citation Analysis]
11 Zhao L, Fu J, Ding F, Liu J, Li L, Song Q, Fu Y. IL-33 and Soluble ST2 Are Associated With Recurrent Spontaneous Abortion in Early Pregnancy. Front Physiol 2022;12:789829. [DOI: 10.3389/fphys.2021.789829] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
12 Nemakayala DR, Cash BD. Excluding inflammatory bowel disease in the irritable bowel syndrome patient: how far to go? Curr Opin Gastroenterol 2019;35:58-62. [PMID: 30407259 DOI: 10.1097/MOG.0000000000000493] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
13 Liu D, Saikam V, Skrada KA, Merlin D, Iyer SS. Inflammatory bowel disease biomarkers. Medicinal Research Reviews. [DOI: 10.1002/med.21893] [Reference Citation Analysis]
14 Zhang Y, Cheng B, Wu ZW, Cui ZC, Song YD, Chen SY, Liu YN, Zhu CJ. Serum soluble suppression of tumorigenicity 2 as a novel inflammatory marker predicts the severity of acute pancreatitis. World J Gastroenterol 2021; 27(38): 6489-6500 [PMID: 34720537 DOI: 10.3748/wjg.v27.i38.6489] [Reference Citation Analysis]
15 Akimoto M, Takenaga K. Role of the IL-33/ST2L axis in colorectal cancer progression. Cell Immunol 2019;343:103740. [PMID: 29329638 DOI: 10.1016/j.cellimm.2017.12.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
16 Krzystek-Korpacka M, Kempiński R, Bromke M, Neubauer K. Biochemical Biomarkers of Mucosal Healing for Inflammatory Bowel Disease in Adults. Diagnostics (Basel) 2020;10:E367. [PMID: 32498475 DOI: 10.3390/diagnostics10060367] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]